Four medicines that treat cancer and inflammatory disease have been added to the Pharmaceutical Benefits Scheme at a cost of $56 million.
The medicines to be extended or listed on the Pharmaceutical Benefits Scheme from Thursday treat brain tumours, leukaemia, and inflammatory disease of the large blood vessels, Health Minister Greg Hunt said in a statement on Sunday.
They are bevacizumab, dasatinib, tocilizumab and lanreotide and will be available for $40.30 per script, or $6.50 with a concession card.
Mr Hunt's statement said the independent Pharmaceutical Benefits Advisory Committee recommended each of the medicines be added to the PBS.
"Unlike Labor, we are subsidising all drugs recommended by the independent medical experts," he said.
The government has added on average 30 medicine listings per month to the PBS since 2013, at a cost of $10.6 billion.